Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.47 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 10/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10118557 | 0.86 | SOS1 (0.47) | MAPTALDH1A1POLBHTTTDP1 | |
| SCHEMBL623663 | 0.82 | TP53 (0.45) | MAPTPKMALDH1A1HSD17B10DUT | |
| SCHEMBL626204 | 0.78 | IL33 (0.46) | MAPTPKMALDH1A1POLBTDP1 | |
| SCHEMBL10118582 | 0.77 | HPGD (0.60) | — | |
| SCHEMBL13539347 | 0.76 | POLB (0.56) | MAPTALDH1A1POLBHTTTDP1 | |
| SCHEMBL2800300 | 0.74 | DUT (0.59) | CYP3A4ALDH1A1DUTDDB1CRBN | |
| SCHEMBL28685578 | 0.72 | LMNA (0.44) | PKMALDH1A1POLBDUT | |
| Ethylene SCHEMBL28028835 | 0.71 | DUT (0.56) | CYP3A4ALDH1A1DUTDDB1CRBN | |
| SCHEMBL10924758 | 0.66 | PKM (0.55) | PKMALDH1A1DUTDDB1CRBN | |
| SCHEMBL4348697 | 0.66 | L3MBTL1 (0.59) | PKMALDH1A1DUTCRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598395-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-03-21 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255088-B2 | Premature-termination-codons readthrough compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-02-19 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
| WO-2012021707-A2 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274283-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | CYP11B1 2248/4885CYP11B2 2485/4885CYP2E1 3425/4885 |
| US-20150051251-A1 | PREMATURE-TERMINATION-CODONS READTHROUGH COMPOUNDS | UPF1, NUDT21, RNGTT | CYP11B1 2248/4885CYP11B2 2485/4885CYP2E1 3425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.